Prosecution Insights
Last updated: May 29, 2026

SK Biopharmaceuticals Co. Ltd.

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
2
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (20%)
2
Easy (40%)
2
Unknown (40%)

Rejection Statute Mix

BucketCases
§103 only1 (20%)
§112 only2 (40%)
No statute on record2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ROZOF, TIMOTHY R 1 72.6% +24.0%
SAEED, KAMAL A 1 84.1% +9.3%
TRAN, SUSAN T 1 62.8% +36.0%
RAO, PADMAJA S 1 69.5% +35.9%
SEITZ, ANTHONY JOSEPH 1 68.8% +28.3%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18210215 BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA SAEED, KAMAL A 28d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17770704 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY SEITZ, ANTHONY JOSEPH 99d overdue
18019856 SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR TRAN, SUSAN T 46d overdue
18565188 METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD) ROZOF, TIMOTHY R 23d overdue
17770686 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION RAO, PADMAJA S 8d overdue

Top Art Units

Art UnitApps
1625 1
1626 1
1615 1
1627 1
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18565188 METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD) ROZOF, TIMOTHY R 1625 §112 Non-Final OA 23d overdue Pending Nov 29, 2023
18210215 BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA SAEED, KAMAL A 1626 §112 Final Rejection 28d Pending Jun 15, 2023
18019856 SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR TRAN, SUSAN T 1615 §103 Final Rejection 46d overdue Pending Feb 06, 2023
17770686 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION RAO, PADMAJA S 1627 Other Non-Final OA 8d overdue Pending Apr 21, 2022
17770704 USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY SEITZ, ANTHONY JOSEPH 1629 Other Final Rejection 99d overdue Pending Apr 21, 2022

Managing SK Biopharmaceuticals Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month